Table 4: Base-case cost-effectiveness results

Treatment	Versus pegylated interferon-ribavirin alone
Treatment	Total cost, $	Total quality adjusted life-years	Incremental cost, $	Incremental quality-adjusted life-years	Incremental cost utility ratio	Sequential incremental cost utility ratio, $
Genotype 1: treatment-naive noncirrhosis*
(0) No treatment	104 904	9.734	-	-	-	-
(1) PR48	114 132	10.839	-	-	-	8 353
(14) PAR/RIT12 + OMB12 + DAS12	143 379	11.835	29 247	0.996	29 354	48 060
(6) SOF12 + LDV12	152 762	11.857	38 631	1.018	37 951	435 528
Genotype 1: treatment-naive cirrhosis*
No treatment	101 355	7.043	-	-	-	-
PR48	120 140	8.659	-	-	-	11 628
SOF12 + LDV12	169 483	10.538	49 344	1.879	26 261	26 261
Genotype 1: treatment-experienced noncirrhosis*
No treatment	104 668	9.596	-	-	-	-
PR48	118 321	10.282	-	-	-	ext. dominated
PAR/RIT12 + OMB12 + DAS12	142 917	11.868	24 597	1.586	15 506	16 836
PAR/RIT12 + OMB12 + DAS12 + RBV12	145 743	11.898	27 422	1.616	16 965	93 872
Genotype 1: treatment-experienced cirrhosis*
No treatment	101 355	7.043	-	-	-	-
PR48	119 828	7.924	-	-	-	ext. dominated
SIM12 PR24-48 RGT	148 780	9.326	28 953	1.402	20 655	20 774
SOF12 + LDV12 + RBV12	172 976	9.933	53 148	2.009	26 456	39 845
SIM12 + SOF12	193 052	9.966	73 225	2.041	35 870	618 881
Genotype 2: treatment-naive noncirrhosis*
PR24	99 904	11.532	-	-	-	-
SOF12 + RBV12	143 955	11.749	44 051	0.217	203 282	203 282
Genotype 2: treatment-naive cirrhosis
No treatment	101 355	7.043	-	-	-	-
PR24	112 767	9.384	-	-	-	4 876
SOF12 + RBV12	159 541	10.181	46 773	0.797	58 659	58 659
Genotype 2: treatment-experienced noncirrhosis*
No treatment	104 668	9.596	-	-	-	-
SOF12 + RBV12	144 023	11.753	39 355	2.157	18 247	18 247
Genotype 2: treatment-experienced cirrhosis*
No treatment	101 355	7.043
SOF12 + PR12	160 863	10.308	59 508	3.265	18 226	18 226
Genotype 3: treatment-naive noncirrhosis*
No treatment	104 183	9.314	-	-	-	-
PR48	110 387	11.156	-	-	-	3 367
DCV12 + SOF12	175 987	11.832	65 600	0.675	97 158	97 158
Genotype 3: treatment-naive cirrhosis
No treatment	101 355	7.043	-	-	-	-
PR48	120 843	9.335	-	-	-	8 504
SOF24 + RBV24	215 437	10.362	94 594	1.027	92 117	92 117
Genotype 3: treatment-experienced noncirrhosis*
No treatment	103 932	9.167	-	-	-	-
PR48	112 301	10.879	8 368	1.712	4 888	4 888
SOF12 + PR12	149 249	11.51	45 316	2.343	19 339	58 535
DCV12 + SOF12	177 476	11.78	73 544	2.612	28 151	104 857
Genotype 3: treatment-experienced cirrhosis
No treatment	101 355	7.043				-
PR48	120 880	8.936	19 525	1.893	10 317	10 317
SOF12 + PR12	163 647	10.082	62 292	3.039	20 496	37 319
SOF24 + RBV24	214 706	9.661	113 351	2.618	43 292	Dominated
Genotype 4: treatment-naive noncirrhosis*
No treatment	104 904	9.734	-	-	-	-
PR48	111 493	11.158	-	-	-	4 627
SOF12 + PR12	145 731	11.698	34 239	0.54	63 421	63 421
Genotype 4: treatment-naive cirrhosis
No treatment	101 355	7.043	-	-	-	-
PR48	120 087	8.608	-	-	-	11 970
SOF24 + RBV24	215 281	10.208	95 194	1.6	59 492	59 492
Genotype 4: treatment-experienced noncirrhosis
No treatment	104 668	9.596	-	-	-
SOF24 + RBV24	201 763	11.503	97 095	1.907	50 913	NA
Genotype 4: treatment-experienced cirrhosis
No treatment	101 355	7.043	-	-	-	NA
SOF24 + RBV24	215 142	10.093	113 787	3.05	37 303

Note: For description of treatment regimens, see Table 1.

*Refer to Appendix 4 for dominated or extendedly dominated treatments.